Quest Diagnostics Urine Markers

2,3-dinor-11β-Prostaglandin F2α (urine) is a stable downstream metabolite of prostaglandin D2 (PGD2)—a mast-cell–derived lipid mediator—measured in spot or 24-hour urine (typically by LC-MS/MS and normalized to creatinine) to provide a noninvasive index of in-vivo PGD2 production and mast-cell activation. Elevated values, interpreted against the lab’s own reference range, can support conditions with mediator release such as mast cell activation syndrome or systemic mastocytosis, allergic reactions and anaphylaxis, aspirin/NSAID-exacerbated respiratory disease, atopic asthma, allergic rhinitis, and chronic spontaneous urticaria; however, it is a supportive—not standalone—marker and should be correlated with symptoms and companion tests (e.g., serum tryptase—including event-related rise of baseline +20%+2 ng/mL—urinary N-methylhistamine, and urinary leukotriene E4). Results are time-sensitive to flares (collect as close to symptoms as possible), and medications can shift levels: NSAIDs/COX-2 inhibitors often suppress prostaglandin synthesis; corticosteroids and mast-cell stabilizers may lower levels over time; biologics and leukotriene modifiers can alter patterns. Normal results do not exclude mast-cell activation due to intermittent release; very low levels may reflect COX inhibition or effective therapy. For trending, use the same lab/method, verify units (e.g., pg/mg creatinine), and document a baseline and flare sample when feasible.

Investigation of Wilson disease and obstructive liver disease

a steroid hormone synthesized from cholesterol

endproduct of creatine metabolism

important indicator of kidney function and overall renal health

Leukotriene E4 (LTE4) is a vital component in the family of leukotrienes, which play a crucial role in the body's inflammatory response. Leukotrienes are chemicals your body releases (for example, when you come into contact with something you're allergic to). As a part of the eicosanoid family, LTE4 is primarily known for its involvement in asthma and allergic reactions, making it a significant target for medical research and treatment strategies. How is Leukotriene E4 (LTE4) formed? The synthesis of leukotrienes, including LTE4, occurs through the metabolism of arachidonic acid, which is a type of fatty acid found in the cell membranes. LTE4 specifically is formed from the sequential conversion of leukotriene A4 (LTA4) to leukotriene C4 (LTC4), and then to leukotriene D4 (LTD4), before finally becoming LTE4. → This process highlights the intricate biochemical pathways involved in inflammation and immune response. In the context of asthma and allergies, LTE4 has been identified as a key mediator. It contributes to a range of symptoms such as: → bronchoconstriction, → increased mucus secretion, → and enhanced vascular permeability, which are hallmark features of these conditions. This has led to the development of various pharmaceutical agents aimed at blocking the effects of LTE4 and other leukotrienes, providing relief for individuals suffering from these chronic conditions. Research into LTE4 has also extended into other areas of health, including its role in cardiovascular diseases and certain types of cancer. Studies are exploring how LTE4’s involvement in inflammatory pathways might influence the development and progression of these diseases, offering new perspectives on treatment and prevention strategies. In summary, Leukotriene E4 is a critical molecule in the field of immunology and inflammation. Its role in asthma, allergies, and potentially in other serious health conditions, underscores the importance of ongoing research in this area. Understanding the mechanisms of LTE4 not only contributes to better management of inflammatory diseases but also opens avenues for new therapeutic interventions in a variety of health disorders. Referenced studies/papers: → A study discussing the functionality of Leukotriene E4 as a full agonist for human cysteinyl leukotriene type 1 receptor-dependent gene expression. This research highlights the significant role of Leukotriene E4 in cellular processes related to gene expression and its potential implications in health and disease [L]. Foster HR, Fuerst E, Branchett W, Lee TH, Cousins DJ, Woszczek G. Leukotriene E4 is a full functional agonist for human cysteinyl leukotriene type 1 receptor-dependent gene expression. Sci Rep. 2016 Feb 2;6:20461. doi: 10.1038/srep20461. PMID: 26830450; PMCID: PMC4735867. → An investigation into the role of urinary Leukotriene E4 as a biomarker in chronic rhinosinusitis, aspirin-exacerbated respiratory disease, and asthma. This comprehensive review emphasizes the diagnostic and prognostic value of Leukotriene E4 in these conditions [L]. Choby G, Low CM, Levy JM, Stokken JK, Pinheiro-Neto C, Bartemes K, Marino M, Han JK, Divekar R, O'Brien EK, Lal D. Urine Leukotriene E4: Implications as a Biomarker in Chronic Rhinosinusitis. Otolaryngol Head Neck Surg. 2022 Feb;166(2):224-232. doi: 10.1177/01945998211011060. Epub 2021 May 11. PMID: 33973823. → A perspective on Leukotriene E4 as a 'forgotten' mediator, detailing its involvement in various physiological and pathological processes, particularly in the context of bronchial asthma and related conditions [L]. Lee TH, Woszczek G, Farooque SP. Leukotriene E4: perspective on the forgotten mediator. J Allergy Clin Immunol. 2009 Sep;124(3):417-21. doi: 10.1016/j.jaci.2009.04.020. Epub 2009 May 30. PMID: 19482346. → Research that associates elevated urine Leukotriene E4 levels with worse objective markers in nasal polyposis patients. This study contributes to the understanding of the role of Leukotriene E4 in nasal polyps and potentially its utility in disease management [L]. Choby G, O'Brien EK, Smith A, Barnes J, Hagan J, Stokken JK, Strumpf A, Mattos JL, Payne SC, Divekar R. Elevated Urine Leukotriene E4 Is Associated With Worse Objective Markers in Nasal Polyposis Patients. Laryngoscope. 2021 May;131(5):961-966. doi: 10.1002/lary.29137. Epub 2020 Oct 1. PMID: 33001452. → A systematic review and meta-analysis focusing on urinary Leukotriene E4 as a biomarker in NSAID-Exacerbated Respiratory Disease (N-ERD). This comprehensive analysis provides insights into the diagnostic and predictive capabilities of Leukotriene E4 in this specific context [L]. Marquette M, Tailor BV, Calder PC, Curtis PJ, Loke Y, Wilson AM. Urinary Leukotriene E4 as a Biomarker in NSAID-Exacerbated Respiratory Disease (N-ERD): a Systematic Review and Meta-analysis. Curr Allergy Asthma Rep. 2022 Dec;22(12):209-229. doi: 10.1007/s11882-022-01049-8. Epub 2022 Nov 14. PMID: 36374376; PMCID: PMC9732072.

a major metabolite of the neurotransmitter histamine

Vanillylmandelic Acid (VMA) is a metabolic breakdown product of certain catecholamines, including epinephrine (adrenaline), norepinephrine (noradrenaline), and dopamine. VMA is excreted in the urine, and its measurement in a random urine sample is used in medical tests to assess the levels of these catecholamines. A Vanillylmandelic Acid, Random Urine test measures the concentration of VMA in a urine sample collected at a random time during the day. This test is often used to help diagnose and monitor conditions related to excessive catecholamine production, such as: → Neuroblastoma: Neuroblastoma is a type of cancer that primarily affects children and can originate in the adrenal glands. Elevated VMA levels can be associated with neuroblastoma, and this test is often used in the diagnosis and monitoring of the disease. → Pheochromocytoma: Pheochromocytoma is a rare tumor that develops in the adrenal glands and can produce excessive amounts of catecholamines. Elevated VMA levels can be a sign of pheochromocytoma. → Paraganglioma: Paragangliomas are tumors similar to pheochromocytomas but can develop in other areas of the body, such as the head, neck, and abdomen. They can also produce elevated levels of catecholamines and VMA. The Vanillylmandelic Acid, Random Urine test helps healthcare providers assess catecholamine metabolism and turnover in the body, which can be informative in diagnosing and monitoring these conditions. It's important to note that while an elevated VMA level can suggest the possibility of these conditions, further evaluation, including imaging studies and clinical assessment, is typically required to confirm or rule out the diagnosis.